FDA reviewing heart risks of Glaxo diabetes pill

(AP)—The Food and Drug Administration will hold a meeting in June to reassess the safety of GlaxoSmithKline's former blockbuster diabetes drug Avandia.

Avandia was severely restricted in 2010 due to concerns about its impact on the heart.

Regulators announced the highly unusual move in a government notice Friday. The FDA will ask a panel of outside experts to review a new analysis of the key study about Avandia's heart risks.

A spokeswoman for Glaxo said the drug company commissioned researchers at Duke University to reanalyze the study, and submitted the results to the FDA last year.

The FDA first approved the drug in 1999 and it became the top-selling in the world by 2006. Sales began plummeting in 2007 after researchers began questioning the drug's safety.


Explore further

Glaxo adds safety restrictions to Avandia label

Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Citation: FDA reviewing heart risks of Glaxo diabetes pill (2013, April 12) retrieved 31 March 2020 from https://medicalxpress.com/news/2013-04-fda-heart-glaxo-diabetes-pill.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments